8TTR | pdb_00008ttr

CA9 mimic bound to SH7

• PDB DOI: https://doi.org/10.2210/pdb8TTR/pdb

• Classification: LYASE/INHIBITOR
• Organism(s): Homo sapiens
• Expression System: Escherichia coli
• Mutation(s): Yes 


• Deposited: 2023-08-14 Released: 2024-11-27 
• Deposition Author(s): Peat, T.S.
• Funding Organization(s): Not funded

---

Experimental Data Snapshot

• Method: X-RAY DIFFRACTION
• Resolution: 1.45 Å
• R-Value Free: 
  0.187 (Depositor), 0.188 (DCC) 
• R-Value Work: 
  0.163 (Depositor), 0.164 (DCC) 

Starting Model: experimental

Literature

4-(Pyrazolyl)benzenesulfonamide Ureas as Carbonic Anhydrases Inhibitors and Hypoxia-Mediated Chemo-Sensitizing Agents in Colorectal Cancer Cells.

Eldehna, W.M., Fares, M., Bonardi, A., Avgenikos, M., Baselious, F., Schmidt, M., Al-Warhi, T., Abdel-Aziz, H.A., Rennert, R., Peat, T.S., Supuran, C.T., Wessjohann, L.A., Ibrahim, H.S.

(2024) J Med Chem 67: 20438-20454

• PubMed: 39550697 
• DOI: https://doi.org/10.1021/acs.jmedchem.4c01894
• Primary Citation of Related Structures:  
  8TTR


• PubMed Abstract: 
  

  Hypoxia in tumors contributes to chemotherapy resistance, worsened by acidosis driven by carbonic anhydrases ( h CA IX and XII). Targeting these enzymes can mitigate acidosis, thus enhancing tumor sensitivity to cytotoxic drugs. Herein, novel 4-(pyrazolyl)benzenesulfonamide ureas ( SH7a-t ) were developed and evaluated for their inhibitory activity against h CA IX and XII. They showed promising results ( h CA IX: K _I = 15.9-67.6 nM, h CA XII: K _I = 16.7-65.7 nM). Particularly, SH7s demonstrated outstanding activity ( K _I s = 15.9 nM for h CA IX and 55.2 nM for h CA XII) and minimal off-target kinase inhibition over a panel of 258 kinases. In NCI anticancer screening, SH7s exhibited broad-spectrum activity with an effective growth inhibition full panel GI ₅₀ (MG-MID) value of 3.5 μM and a subpanel GI ₅₀ (MG-MID) range of 2.4-6.3 μM. Furthermore, SH7s enhanced the efficacy of Taxol and 5-fluorouracil in cotreatment regimens under hypoxic conditions in HCT-116 colorectal cancer cells, indicating its potential as a promising anticancer agent.

---

Organizational Affiliation: 
• Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh 33516, Egypt.
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Pharos University in Alexandria, Canal El Mahmoudia Street, Alexandria 21648, Egypt.
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Egyptian Russian University, Badr City, Cairo 11829, Egypt.
Sydney Pharmacy School, The University of Sydney, Sydney, New South Wales 2006, Australia.
Department NEUROFARBA─Pharmaceutical and Nutraceutical Section, University of Firenze, via Ugo Schiff 6, Sesto Fiorentino I-50019, Firenze, Italy.
Department of Bioorganic Chemistry, Leibniz Institute of Plant Biochemistry, Halle (Saale) D-06120, Germany.
Department of Medicinal Chemistry, Institute of Pharmacy, Martin-Luther-University of Halle-Wittenberg, Halle (Saale) D-06120, Germany.
Department of Chemistry, College of Science, Princess Nourah Bint Abdulrahman University, Riyadh 11564, Saudi Arabia.
Applied Organic Chemistry Department, National Research Center, Dokki, Giza 12622, Cairo, Egypt.
School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, New South Wales 2052, Australia.

Biological Assembly 1  

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Monomer - A1 

Biological assembly 1 assigned by authors and generated by PISA (software)

Macromolecule Content 

• Total Structure Weight: 30.07 kDa 
• Atom Count: 2,436 
• Modeled Residue Count: 259 
• Deposited Residue Count: 260 
• Unique protein chains: 1

Macromolecules

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details	Image
Carbonic anhydrase 2	A	260	Homo sapiens	Mutation(s): 10  Gene Names: CA2 EC: 4.2.1.1 (PDB Primary Data), 4.2.1.69 (UniProt)
UniProt & NIH Common Fund Data Resources
Find proteins for P00918 (Homo sapiens) Explore P00918  Go to UniProtKB:  P00918
PHAROS:  P00918 GTEx:  ENSG00000104267

Small Molecules

Ligands 5 Unique
ID	Chains	Name / Formula / InChI Key	2D Diagram
LGO (Subject of Investigation/LOI)	C [auth A]	4-{5-phenyl-4-[(4-sulfamoylphenyl)carbamamido]-1H-pyrazol-1-yl}benzene-1-sulfonamide C22 H20 N6 O5 S2 ZOOBJKVJHXVCFM-UHFFFAOYSA-N
SO4	F [auth A]	SULFATE ION O4 S QAOWNCQODCNURD-UHFFFAOYSA-L
GOL	E [auth A]	GLYCEROL C3 H8 O3 PEDCQBHIVMGVHV-UHFFFAOYSA-N
DMS	D [auth A]	DIMETHYL SULFOXIDE C2 H6 O S IAZDPXIOMUYVGZ-UHFFFAOYSA-N
ZN	B [auth A]	ZINC ION Zn PTFCDOFLOPIGGS-UHFFFAOYSA-N

Experimental Data & Validation

Experimental Data

• Method: X-RAY DIFFRACTION
• Resolution: 1.45 Å
• R-Value Free:  0.187 (Depositor), 0.188 (DCC) 
• R-Value Work:  0.163 (Depositor), 0.164 (DCC) 

Space Group: P 1 2₁ 1

Unit Cell:

Length ( Å )	Angle ( ˚ )
a = 42.16	α = 90
b = 41.514	β = 104.131
c = 72.065	γ = 90

Software Package:

Software Name	Purpose
REFMAC	refinement
XDS	data reduction
Aimless	data scaling
PHASER	phasing

Structure Validation

Entry History & Funding Information

Deposition Data

• Released Date: 2024-11-27 
Deposition Author(s): Peat, T.S.

---

Funding Organization	Location	Grant Number
Not funded		--

Revision History  

• Version 1.0: 2024-11-27
  Type: Initial release
  
• Version 1.1: 2024-12-11
  Changes: Database references